 |
- Visit the Icotinib Website for further details: www.icotinib-global.com
- Orally administered, highly potent and selective inhibitor of EGFR and its activating mutations
- Phase I/II clinical trials demonstrated anti-tumor activity in NSCLC; a recently completed randomized double-blind, multiple-center Phase III trial comparing to gefitinib is currently being evaluated
- Better safety profile compared to traditional therapeutics and treatment with standard drugs
- Broad anti-tumor activity, producing stasis and regression in other cancers
- Exclusive world-wide patent coverage through 2027
|
|
